SCHEMBL9937529

SCHEMBL9937529

O=C(O)c1ccc(Cc2cccc(F)c2)cc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.51
HNF4A P41235 1/20 0.50
RXRA P19793 2/20 0.49
MAOB P27338 1/20 0.49
SNCA P37840 1/20 0.47
KLKB1 P03952 1/20 0.47
CTSB P07858 1/20 0.47
MMP9 P14780 1/20 0.47
DNMT1 P26358 1/20 0.47
DNMT3B Q9UBC3 1/20 0.47
DNMT3L Q9UJW3 1/20 0.47
DNMT3A Q9Y6K1 1/20 0.47
NR4A2 P43354 2/20 0.47
DCLRE1B Q9H816 1/20 0.47
ALDH1A1 P00352 1/20 0.46
CDC25B P30305 1/20 0.46
CASP6 P55212 1/20 0.46
RCE1 Q9Y256 1/20 0.46
BRS3 P32247 1/20 0.46
RXRB P28702 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9938816 0.83 MAOB (0.50) MAOBSNCAALDH1A1TAAR1
SCHEMBL19910415 0.83 MEN1 (0.51) HCAR2MAOBALDH1A1
SCHEMBL9938831 0.81 NR4A2 (0.63) HCAR2RXRANR4A2RXRBRXRG
SCHEMBL28105342 0.81 HCAR2 (0.52) HCAR2HNF4ANR4A2DCLRE1BBRS3
SCHEMBL9937934 0.79 NR4A2 (0.63) HCAR2NR4A2SLC1A1
SCHEMBL28117926 0.79 TSHR (0.57) HCAR2HNF4ANR4A2DCLRE1BBRS3
SCHEMBL28780702 0.78 NR4A2 (0.55) HCAR2NR4A2SLC1A1
SCHEMBL3300303 0.78 TAAR1 (0.60) HCAR2MAOBALDH1A1TAAR1
SCHEMBL11821214 0.77 DCLRE1B (0.48) HCAR2RXRAMAOBNR4A2DCLRE1B
SCHEMBL4424360 0.77 MAOB (0.80) MAOBNR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084056-A1 SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-03-13 US disclosed
EP-2651888-B1 N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders UNIV LEUVEN KATH (BE) 2017-05-17 EP disclosed
CN-103261156-B For treating the noval chemical compound of neurodegenerative disease 鲁汶天主教大学研究开发部 2016-12-28 CN disclosed
US-9266832-B2 Compounds for the treatment of neurodegenerative diseases Katholieke Universiteit Levun (BE) 2016-02-23 US disclosed
EP-2651888-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven K.U. Leuven R&D (BE) 2013-10-23 EP disclosed
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2013-10-17 US disclosed
WO-2012080221-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084056-A1 SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS CCNA1, CCNI, CCNE1 HCAR2 3600/4885HNF4A 2415/4885RXRA 2260/4885
US-20130274260-A1 NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, PSEN1 HCAR2 3718/4885HNF4A 3991/4885RXRA 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.